|
The New Future of Biotechnology: Enabling Technologies and Star ProductsPublished by: BCC Research Published: Jan. 1, 2001 - 199 Pages Table of Contents Introduction
Summary Overview
Enabling Technologies
Products: Therapeutic Antibodies And Gene Therapy
Gene Therapy
The Market For Enabling Technologies, Therapeutic Antibodies, Gene Therapy And Antisense
The Resurgent Biotechnology Industry
Profiles Of Selected Biotechnology Companies
List Of Tables
The Market For Selected Biotechnology Enabling Technologies And Products, Through 2005 1 Potential Blockbuster Drugs In The Near Future 2 Biotech Drugs Awaiting Fda Approval In July 2000 3 Worldwide Sales Of Selected Biotechnology Drugs, 1999 4 The Market For Medical Biotechnology Products, Through 2005 5 High-Throughput Technologies Used In Analysis Of Gene Expression Levels 6 Selected Human Proteins In Development As Drugs 7 Major Players In The Various Genomics And Post-Genomics Technologies 8 Selected Competitors In The Biochip Market 9 Feature Comparisons Of Selected Array Technologies 10 Emerging Technologies In The Field Of Proteomics 11 Biotechnology Companies Involved In Proteomics 12 The Snp Consortium 13 The Impact Of Genomics And Pharmocogenomics On Medicine And Disease Treatment 14 Major Players In The Pharmacogenomics Market 15 Bioinformatics Technology: Areas, Applications And Obstacles 16 Technologies And Research Associated With Dna Sequencing Data 17 Technologies And Research Associated With Gene Expression Data 18 Technologies And Research Associated With Protein Data 19 Technologies And Research Associated With Medical Genetics Data 20 Selected Companies In The Bioinformatics Business 21 Antibodies In Development For Autoimmune Disorders 22 Antibodies In Development For Blood Disorders 23 Antibodies In Development For Cancer And Related Conditions 24 Antibodies In Development For Digestive Disorders 25 Antibodies In Development For Eye Disorders 26 Antibodies In Development For Heart Disease 27 Antibodies In Development For Infectious Diseases 28 Antibodies In Development For Neurological Disorders 29 Antibodies In Development For Respiratory Diseases 30 Antibodies In Development For Skin Disorders 31 Antibodies In Development For Transplantation Applications 32 Antibodies In Development For Other Indications 33 Selected Gene Therapy Clinical Trials Currently Underway 34 Selected Gene Therapy Drugs Under Development Based On Disease Categories 35 Major Antisense Technologies 36 Selected Antisense Drug Clinical Trials Currently Underway 37 Companies Developing Antisense Drugs 38 Applications Markets For Genomics-Based Products And Services, Through 2005 39 The Market For Gene Sequencing, Through 2005 40 The Market For Microarrays Used In Polymorphism Analysis, Through 2005 41 The Market For Gene Expression, Through 2005 42 The Market For Viral Genotyping, Through 2005 43 The Market For Microarrays (Dna Chips), Through 2005 44 The Market For Proteomics, Through 2005 45 The Market For Pharmacogenomic Services And Devices, Through 2005 46 The Market For Bioinformatics, Through 2005 47 Worldwide Sales Of Polyclonal And Monoclonal Antibodies As Drugs, Through 2005 48 Selected Polyclonal Antibodies: Worldwide Sales, Through 2005 49 Selected Therapeutic Monoclonal Antibodies: Worldwide Sales, Through 2005 50 Therapeutic Applications Of Selected Antibodies: Worldwide Sales, Through 2005 51 The Market For Cancer Gene Therapy Drugs: 2000 And 2005 52 The Market For Gene Therapy Drugs (Excluding Cancer), 2000 And 2005 53 The Market For Gene Therapy Products, 2000 And 2005 54 The Market For Antisense Drugs, Through 2005 55 Biotechnology Companies Making Profits, Through 2001 56 Top Ten Publicly Owned Biotechnology Companies, 1999 57 R&D Expenditires By The Top 20 Biotechnology Companies, 1999 58 Research And Development Expenditures, 1988 And 1998 59 Biologics-Based Chemical-Based Drugs For Various Diseases In Development 60 Top Tier Companies 61 Abgenix' S Xenomouse Technology Collaborators 62 Abgenix's Antibody Drugs In Clinical Trials 63 Affymetrix's Revenues For Genechip Products And Subscription Fees, 1998-2003 64 Selected Affymetrix Customers 65 Affymetrix's Product Portfolio 66 Curagen's Collaborative Alliances 67 Genome Therapeutics' Collaborative Agreements 68 Genomics Solutions' Collaborators 69 Genzyme Corp. And Genzyme Transgenics Development Pipeline 70 Idec's Collaborative Arrangements 71 Idec's Product Pipeline 72 Incyte's Revenues, Through 2004 73 Applications Of Incyte's Technologies 74 Isis'S Drug Pipeline 75 Medarex's Drug Development Pipeline 76 Myriad Genetics' Strategic Alliances 77 Myriad Genetics' Gene-Based Products/Discovery Pipeline 78 Myriad Genetics' Pipeline Of Near-Term Gene Discoveries 79 Ogs's Proteomics Alliances 80 Pdl's Antibody Products 81 Targeted Genetics Products In Clinical Trials 82 Targeted Genetics' Collaborators List Of Figures
The Market For Selected Biotechnology Enabling Technologies And Products, Through 2005 1 Biotechnology Medicines Entering Clinical Trials, Through 2000 2 Percentage Of Genomics-Based Drugs By Therapeutic Category, 2000 And 2005 3 Drug Development Using Bioinformatics 4 Market Share Held By Bioinformatics Providers, Through 2005 5 Evolution Of Therapeutic Mabs 6 Antisense Drug Action 7 Antisense Drug Development 8 Applications Markets For Genomics-Based Products And Services, 1999-2005 9 The Market For Gene Expression, Through 2005 10 The Market For Viral Genotyping, 1999-2005 11 The Market For Microarrays (Dna Chips), 1999-2005 12 The Market For Pharmacogenomic Services And Devices, 1999-2005 13 Worldwide Sales Of Polyclonal And Monoclonal Antibodies As Drugs, 1999-2005 14 Therapeutic Applications Of Selected Antibodies: Worldwide Sales, 1999-2005 15 Convergence Of Biotechnology And Chemistry In Therapeutic Drug Development AbstractThis report from BCC focuses on three of the emerging "stars" of biotechnology: genomics (including proteomics, pharmacogenomics and bioinformatics), gene therapy, antisense drugs and antibodies. Market estimates are provided for genomics, proteomics, pharmacogenomics, bioinformatics, gene therapy treatments for cancer and for other disorders, antisense drugs and antibodies. The forecast period is 1999 to 2005, and the scope of the market is worldwide. A detailed discussion and analysis of the effect of these products on the treatment of disease and the overall health care market are provided, along with comparative profiles of leading and emerging companies in the areas covered in this report.Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||